Dietary walnut reduces hepatic triglyceride content in high-fat-fed mice via modulation of hepatic fatty acid metabolism and adipose tissue inflammation

Journal of Nutritional Biochemistry

Volumn 30, Issue , 2016, Pages 116-125

  Choi, Youngshim ^a   Abdelmegeed, Mohamed A ^a   Akbar, Mohammed ^a   Song, Byoung Joon ^a  

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

Adipose tissue; High fat diet; Inflammation; Liver; Steatosis; Triglyceride; Walnut

Indexed keywords

CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; FATTY ACID SYNTHASE; GLYCOPROTEIN P 15095; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INTERLEUKIN 10; INTERLEUKIN 6; LIVER PROTEIN; MACROPHAGE DERIVED CHEMOKINE; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; FATTY ACID;

ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BODY WEIGHT; CELL INFILTRATION; COMPARATIVE STUDY; CONTROLLED STUDY; DIET SUPPLEMENTATION; DIETARY INTAKE; FATTY ACID METABOLISM; FATTY LIVER; GENE EXPRESSION; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE; HISTOPATHOLOGY; INFLAMMATION; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LIPID DIET; LIPID HOMEOSTASIS; LIPID LIVER LEVEL; LIPID STORAGE; LIVER PROTECTION; MALE; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WALNUT; WEIGHT GAIN; ANIMAL; LIVER; METABOLISM; PATHOLOGY;

ADIPOSE TISSUE; ANIMALS; DIET, HIGH-FAT; FATTY ACIDS; INFLAMMATION; JUGLANS; LIVER; MICE; TRIGLYCERIDES;

EID: 84962129330     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2015.12.005     Document Type: Article

References (64)

1. Dowman J.K., Tomlinson J.W., Newsome P.N. Pathogenesis of non-alcoholic fatty liver disease. QJM 2010, 103:71-83.
2. Chang E., Park C.Y., Park S.W. Role of thiazolidinediones, insulin sensitizers, in non-alcoholic fatty liver disease. J Diabetes Investig 2013, 4:517-524.
3. Zhang B.B., Zhou G., Li C. AMPK: an emerging drug target for diabetes and the metabolic syndrome. Cell Metab 2009, 9:407-416.
4. Abdelmegeed M.A., Yoo S.H., Henderson L.E., Gonzalez F.J., Woodcroft K.J., Song B.J. PPARalpha expression protects male mice from high fat-induced nonalcoholic fatty liver. J Nutr 2011, 141:603-610.
5. Duval C., Thissen U., Keshtkar S., Accart B., Stienstra R., Boekschoten M.V., et al. Adipose tissue dysfunction signals progression of hepatic steatosis towards nonalcoholic steatohepatitis in C57BL/6 mice. Diabetes 2010, 59:3181-3191.
6. Ouchi N., Parker J.L., Lugus J.J., Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol 2011, 11:85-97.
7. Kotronen A., Westerbacka J., Bergholm R., Pietilainen K.H., Yki-Jarvinen H. Liver fat in the metabolic syndrome. J Clin Endocrinol Metab 2007, 92:3490-3497.
8. Olefsky J.M., Glass C.K. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 2010, 72:219-246.
9. Kolak M., Westerbacka J., Velagapudi V.R., Wagsater D., Yetukuri L., Makkonen J., et al. Adipose tissue inflammation and increased ceramide content characterize subjects with high liver fat content independent of obesity. Diabetes 2007, 56:1960-1968.
10. Apovian C.M., Bigornia S., Mott M., Meyers M.R., Ulloor J., Gagua M., et al. Adipose macrophage infiltration is associated with insulin resistance and vascular endothelial dysfunction in obese subjects. Arterioscler Thromb Vasc Biol 2008, 28:1654-1659.
11. Le K.A., Mahurkar S., Alderete T.L., Hasson R.E., Adam T.C., Kim J.S., et al. Subcutaneous adipose tissue macrophage infiltration is associated with hepatic and visceral fat deposition, hyperinsulinemia, and stimulation of NF-kappaB stress pathway. Diabetes 2011, 60:2802-2809.
12. Kanda H., Tateya S., Tamori Y., Kotani K., Hiasa K., Kitazawa R., et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 2006, 116:1494-1505.
13. Strissel K.J., Stancheva Z., Miyoshi H., Perfield J.W., DeFuria J., Jick Z., et al. Adipocyte death, adipose tissue remodeling, and obesity complications. Diabetes 2007, 56:2910-2918.
14. Murano I., Barbatelli G., Parisani V., Latini C., Muzzonigro G., Castellucci M., et al. Dead adipocytes, detected as crown-like structures, are prevalent in visceral fat depots of genetically obese mice. J Lipid Res 2008, 49:1562-1568.
15. Cinti S., Mitchell G., Barbatelli G., Murano I., Ceresi E., Faloia E., et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res 2005, 46:2347-2355.
16. Firenzuoli F., Gori L. Herbal medicine today: clinical and research issues. Evid Based Complement Alternat Med 2007, 4:37-40.
17. Berryman C.E., Grieger J.A., West S.G., Chen C.Y., Blumberg J.B., Rothblat G.H., et al. Acute consumption of walnuts and walnut components differentially affect postprandial lipemia, endothelial function, oxidative stress, and cholesterol efflux in humans with mild hypercholesterolemia. J Nutr 2013, 143:788-794.
18. Mullner E., Brath H., Pleifer S., Schiermayr C., Baierl A., Wallner M., et al. Vegetables and PUFA-rich plant oil reduce DNA strand breaks in individuals with type 2 diabetes. Mol Nutr Food Res 2013, 57:328-338.
19. Anand R., Kaithwas G. Anti-inflammatory potential of alpha-linolenic acid mediated through selective COX inhibition: computational and experimental data. Inflammation 2014, 37:1297-1306.
20. Fink A., Rufer C.E., Le Grandois J., Roth A., Aoude-Werner D., Marchioni E., et al. Dietary walnut oil modulates liver steatosis in the obese zucker rat. Eur J Nutr 2014, 53:645-660.
21. Davis P.A., Vasu V.T., Gohil K., Kim H., Khan I.H., Cross C.E., et al. A high-fat diet containing whole walnuts (Juglans regia) reduces tumour size and growth along with plasma insulin-like growth factor 1 in the transgenic adenocarcinoma of the mouse prostate model. Br J Nutr 2012, 108:1764-1772.
22. Nagel J.M., Brinkoetter M., Magkos F., Liu X., Chamberland J.P., Shah S., et al. Dietary walnuts inhibit colorectal cancer growth in mice by suppressing angiogenesis. Nutrition 2012, 28:67-75.
23. Kleiner D.E., Brunt E.M., Van Natta M., Behling C., Contos M.J., Cummings O.W., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41:1313-1321.
24. Abdelmegeed M.A., Banerjee A., Yoo S.H., Jang S., Gonzalez F.J., Song B.J. Critical role of cytochrome P450 2E1 (CYP2E1) in the development of high fat-induced non-alcoholic steatohepatitis. J Hepatol 2012, 57:860-866.
25. Amarapurkar D.N., Hashimoto E., Lesmana L.A., Sollano J.D., Chen P.J., Goh K.L., et al. How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences?. J Gastroenterol Hepatol 2007, 22:788-793.
26. Das K., Das K., Mukherjee P.S., Ghosh A., Ghosh S., Mridha A.R., et al. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease. Hepatology 2010, 51:1593-1602.
27. Kanuri G., Spruss A., Wagnerberger S., Bischoff S.C., Bergheim I. Role of tumor necrosis factor alpha (TNFalpha) in the onset of fructose-induced nonalcoholic fatty liver disease in mice. J Nutr Biochem 2011, 22:527-534.
28. Spruss A., Kanuri G., Uebel K., Bischoff S.C., Bergheim I. Role of the inducible nitric oxide synthase in the onset of fructose-induced steatosis in mice. Antioxid Redox Signal 2011, 14:2121-2135.
29. Schultz A., Barbosa-da-Silva S., Aguila M.B., Mandarim-de-Lacerda C.A. Differences and similarities in hepatic lipogenesis, gluconeogenesis and oxidative imbalance in mice fed diets rich in fructose or sucrose. Food Funct 2015, 6:1684-1691.
30. Song Z., Deaciuc I., Zhou Z., Song M., Chen T., Hill D., et al. Involvement of AMP-activated protein kinase in beneficial effects of betaine on high-sucrose diet-induced hepatic steatosis. Am J Physiol Gastrointest Liver Physiol 2007, 293:G894-G902.
31. Do G.M., Kwon E.Y., Ha T.Y., Park Y.B., Kim H.J., Jeon S.M., et al. Tannic acid is more effective than clofibrate for the elevation of hepatic beta-oxidation and the inhibition of 3-hydroxy-3-methyl-glutaryl-CoA reductase and aortic lesion formation in apo E-deficient mice. Br J Nutr 2011, 106:1855-1863.
32. Stienstra R., Mandard S., Patsouris D., Maass C., Kersten S., Muller M. Peroxisome proliferator-activated receptor alpha protects against obesity-induced hepatic inflammation. Endocrinology 2007, 148:2753-2763.
33. Brooks S.C., Brooks J.S., Lee W.H., Lee M.G., Kim S.G. Therapeutic potential of dithiolethiones for hepatic diseases. Pharmacol Ther 2009, 124:31-43.
34. Lin H.Z., Yang S.Q., Chuckaree C., Kuhajda F., Ronnet G., Diehl A.M. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med 2000, 6:998-1003.
35. Bajaj M., Suraamornkul S., Pratipanawatr T., Hardies L.J., Pratipanawatr W., Glass L., et al. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes 2003, 52:1364-1370.
36. Schafer H.L., Linz W., Falk E., Glien M., Glombik H., Korn M., et al. AVE8134, a novel potent PPARalpha agonist, improves lipid profile and glucose metabolism in dyslipidemic mice and type 2 diabetic rats. Acta Pharmacol Sin 2012, 33:82-90.
37. Peschel D., Koerting R., Nass N. Curcumin induces changes in expression of genes involved in cholesterol homeostasis. J Nutr Biochem 2007, 18:113-119.
38. Patsouris D., Reddy J.K., Muller M., Kersten S. Peroxisome proliferator-activated receptor alpha mediates the effects of high-fat diet on hepatic gene expression. Endocrinology 2006, 147:1508-1516.
39. Farese R.V., Zechner R., Newgard C.B., Walther T.C. The problem of establishing relationships between hepatic steatosis and hepatic insulin resistance. Cell Metab 2012, 15:570-573.
40. Cohen J.C., Horton J.D., Hobbs H.H. Human fatty liver disease: old questions and new insights. Science 2011, 332:1519-1523.
41. Sun Z., Lazar M.A. Dissociating fatty liver and diabetes. Trends Endocrinol Metab 2013, 24:4-12.
42. Brennan A.M., Sweeney L.L., Liu X., Mantzoros C.S. Walnut consumption increases satiation but has no effect on insulin resistance or the metabolic profile over a 4-day period. Obesity 2010, 18:1176-1182.
43. Mukuddem-Petersen J., Stonehouse Oosthuizen W., Jerling J.C., Hanekom S.M., White Z. Effects of a high walnut and high cashew nut diet on selected markers of the metabolic syndrome: a controlled feeding trial. Br J Nutr 2007, 97:1144-1153.
44. Zhao G., Etherton T.D., Martin K.R., Gillies P.J., West S.G., Kris-Etherton P.M. Dietary alpha-linolenic acid inhibits proinflammatory cytokine production by peripheral blood mononuclear cells in hypercholesterolemic subjects. Am J Clin Nutr 2007, 85:385-391.
45. Jimenez-Gomez Y., Lopez-Miranda J., Blanco-Colio L.M., Marin C., Perez-Martinez P., Ruano J., et al. Olive oil and walnut breakfasts reduce the postprandial inflammatory response in mononuclear cells compared with a butter breakfast in healthy men. Atherosclerosis 2009, 204:e70-e76.
46. Kanneganti T.D., Dixit V.D. Immunological complications of obesity. Nat Immunol 2012, 13:707-712.
47. Xu H., Barnes G.T., Yang Q., Tan G., Yang D., Chou C.J., et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003, 112:1821-1830.
48. Weisberg S.P., Hunter D., Huber R., Lemieux J., Slaymaker S., Vaddi K., et al. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest 2006, 116:115-124.
49. Tamura Y., Sugimoto M., Murayama T., Minami M., Nishikaze Y., Ariyasu H., et al. C-C chemokine receptor 2 inhibitor improves diet-induced development of insulin resistance and hepatic steatosis in mice. J Atheroscler Thromb 2010, 17:219-228.
50. Kitade H., Sawamoto K., Nagashimada M., Inoue H., Yamamoto Y., Sai Y., et al. CCR5 plays a critical role in obesity-induced adipose tissue inflammation and insulin resistance by regulating both macrophage recruitment and M1/M2 status. Diabetes 2012, 61:1680-1690.
51. Clement S., Juge-Aubry C., Sgroi A., Conzelmann S., Pazienza V., Pittet-Cuenod B., et al. Monocyte chemoattractant protein-1 secreted by adipose tissue induces direct lipid accumulation in hepatocytes. Hepatology 2008, 48:799-807.
52. Alkhouri N., Gornicka A., Berk M.P., Thapaliya S., Dixon L.J., Kashyap S., et al. Adipocyte apoptosis, a link between obesity, insulin resistance, and hepatic steatosis. J Biol Chem 2010, 285:3428-3438.
53. Alvheim A.R., Malde M.K., Osei-Hyiaman D., Lin Y.H., Pawlosky R.J., Madsen L., et al. Dietary linoleic acid elevates endogenous 2-AG and anandamide and induces obesity. Obesity 2012, 20:1984-1994.
54. Abe M., Matsuda M., Kobayashi H., Miyata Y., Nakayama Y., Komuro R., et al. Effects of statins on adipose tissue inflammation: their inhibitory effect on MyD88-independent IRF3/IFN-beta pathway in macrophages. Arterioscler Thromb Vasc Biol 2008, 28:871-877.
55. DeFuria J., Bennett G., Strissel K.J., Perfield J.W., Milbury P.E., Greenberg A.S., et al. Dietary blueberry attenuates whole-body insulin resistance in high fat-fed mice by reducing adipocyte death and its inflammatory sequelae. J Nutr 2009, 139:1510-1516.
56. Gao M., Zhang C., Ma Y., Bu L., Yan L., Liu D. Hydrodynamic delivery of mIL10 gene protects mice from high-fat diet-induced obesity and glucose intolerance. Mol Ther 2013, 21:1852-1861.
57. Gao M., Ma Y., Liu D. Rutin suppresses palmitic acids-triggered inflammation in macrophages and blocks high fat diet-induced obesity and fatty liver in mice. Pharm Res 2013, 30:2940-2950.
58. Gerner R.R., Wieser V., Moschen A.R., Tilg H. Metabolic inflammation: role of cytokines in the crosstalk between adipose tissue and liver. Can J Physiol Pharmacol 2013, 91:867-872.
59. Ma Y., Gao M., Liu D. Chlorogenic acid improves high fat diet-induced hepatic steatosis and insulin resistance in mice. Pharm Res 2015, 32:1200-1209.
60. Crespo J., Cayon A., Fernandez-Gil P., Hernandez-Guerra M., Mayorga M., Dominguez-Diez A., et al. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 2001, 34:1158-1163.
61. Zhou Y.J., Li Y.Y., Nie Y.Q., Yang H., Zhan Q., Huang J., et al. Influence of polygenetic polymorphisms on the susceptibility to non-alcoholic fatty liver disease of Chinese people. J Gastroenterol Hepatol 2010, 25:772-777.
62. Kishimoto T. IL-6: from its discovery to clinical applications. Int Immunol 2010, 22:347-352.
63. Oliveira M.C., Menezes-Garcia Z., Henriques M.C., Soriani F.M., Pinho V., Faria A.M., et al. Acute and sustained inflammation and metabolic dysfunction induced by high refined carbohydrate-containing diet in mice. Obesity 2013, 21:E396-E406.
64. Esposito K., Pontillo A., Di Palo C., Giugliano G., Masella M., Marfella R., et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 2003, 289:1799-1804.